WOCKPHARMA

Wockhardt Share Price

 

 

Invest in Wockhardt with 2.46X leverage

Invest with MTF

Performance

  • Low
  • ₹1,312
  • High
  • ₹1,378
  • 52 Week Low
  • ₹1,110
  • 52 Week High
  • ₹1,869
  • Open Price₹1,322
  • Previous Close₹1,322
  • Volume1,136,392

Investment Returns

  • Over 1 Month -0.31%
  • Over 3 Month -10.73%
  • Over 6 Month -11.69%
  • Over 1 Year -4.46%

Smart Investing Starts Here Start SIP with Wockhardt for Steady Growth!

Invest Now

Wockhardt Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -942.1
  • PEG Ratio
  • -10.2
  • Market Cap Cr
  • 21,668
  • P/B Ratio
  • Average True Range
  • 64.49
  • EPS
  • 4.34
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.35
  • RSI
  • 48.48
  • MFI
  • 70.72

Wockhardt Financials

Wockhardt Technicals

EMA & SMA

Current Price
₹1,333.50
+ 11.6 (0.88%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹1,344.69
  • 50 Day
  • ₹1,371.67
  • 100 Day
  • ₹1,413.30
  • 200 Day
  • ₹1,395.99

Resistance and Support

1341.2 Pivot Speed
  • R3 1,435.90
  • R2 1,406.90
  • R1 1,370.20
  • S1 1,304.50
  • S2 1,275.50
  • S3 1,238.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wockhardt Ltd. is a global pharmaceutical and biotechnology company specializing in the development, manufacturing, and marketing of medicines, vaccines, and biosimilars. It focuses on key therapeutic areas including anti-infectives, cardiology, and diabetes care.

Wockhardt has an operating revenue of Rs. 2,984.00 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of -1% needs improvement, ROE of -1% is poor and needs improvement. The company has a reasonable debt to equity of 28%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wockhardt Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-03 Quarterly Results
2025-08-08 Quarterly Results
2025-05-29 Audited Results & Fund Raising
2025-02-07 Quarterly Results
2024-11-13 Quarterly Results

Wockhardt F&O

Wockhardt Shareholding Pattern

49.08%
7.89%
0.66%
7.1%
0%
26.1%
9.17%

About Wockhardt

  • NSE Symbol
  • WOCKPHARMA
  • BSE Symbol
  • 532300
  • Managing Director
  • Dr. Murtaza Khorakiwala
  • ISIN
  • INE049B01025

Similar Stocks to Wockhardt

Wockhardt FAQs

Wockhardt share price is ₹1,333 As on 11 December, 2025 | 03:31

The Market Cap of Wockhardt is ₹21668.3 Cr As on 11 December, 2025 | 03:31

The P/E ratio of Wockhardt is -942.1 As on 11 December, 2025 | 03:31

The PB ratio of Wockhardt is 6.4 As on 11 December, 2025 | 03:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23